100% Secure Checkout Secure
Third-Party HPLC Tested HPLC Tested
Accurately measure your GLP-1/GIP/GCGR tri-agonist research protocols. Enter your vial size, bacteriostatic water volume, and desired dose to calculate the exact syringe draw.
Standard Retatrutide vials are typically 5mg, 10mg, or 15mg.
Volume of water used to reconstitute the lyophilized powder.
Retatrutide is often dosed in mg increments (e.g., 2mg, 4mg).
Select the maximum capacity of your U-100 insulin syringe.
Draw exactly to the 40 unit mark (red line) on a 1mL (100 Unit) insulin syringe.
Concentration
5.00 mg/mL
Dose per Unit (1/100 mL)
50.0 mcg/Unit
Volume to Inject
0.40 mL
Select a research protocol below to view its specific week-by-week titration chart.
| Phase | Timeline | Weekly Dosage |
|---|---|---|
| Initiation | Weeks 1 - 4 | 2.0 mg |
| Titration 1 | Weeks 5 - 8 | 4.0 mg |
| Titration 2 | Weeks 9 - 12 | 6.0 mg |
| Maintenance | Weeks 13+ | 8.0 - 12.0 mg |
Standard clinical trial escalation. Monitor resting heart rate and gastrointestinal motility. If nausea is severe at 4.0mg, delay Titration 2 by an additional 2 weeks.
Tri-agonist (GLP-1/GIP/Glucagon)
A highly potent triple hormone receptor agonist primarily researched for significant weight management and metabolic improvements.
Unlike dual-agonists (like Tirzepatide), Retatrutide uniquely incorporates glucagon receptor (GCGR) agonism. This specific mechanism is what separates it from earlier generations of weight loss peptides.
While GLP-1 and GIP suppress appetite and increase insulin sensitivity, the addition of glucagon agonism directly stimulates the liver to increase energy expenditure (thermogenesis) and rapidly clear hepatic lipid stores.
Result: This tri-agonist effect causes unprecedented reductions in adiposity in clinical models, often surpassing the results of gastric bypass surgery equivalents in trials.
Lyophilized Retatrutide is highly fragile prior to reconstitution. Store unmixed vials in the freezer (-20°C) for long-term preservation. Once reconstituted with Bacteriostatic Water, the peptide must be refrigerated (2°C - 8°C) to prevent rapid degradation.
Retatrutide exhibits an extended half-life of approximately 6 days, which supports a convenient once-weekly subcutaneous administration schedule in most clinical models.
Due to this pharmacokinetic profile, steady-state blood plasma concentrations are typically reached after 4 to 5 weeks of continuous dosing. Researchers are advised against premature dose escalation before this steady-state is achieved to accurately gauge tolerability.
Current pharmacological research models suggest Retatrutide should be strictly excluded in subjects with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Monitoring: Close monitoring of pancreatic enzyme markers (lipase and amylase) alongside resting heart rate (RHR) is strongly advised throughout the duration of the protocol.